Author
Home > Health > What is the Difference Between Lenalidomide and Thalidomide?

Guilherme Mazui

•2 minutes to read

What is the Difference Between Lenalidomide and Thalidomide?

🆚 Go to Comparative Table 🆚

Lenalidomide and thalidomide are both immunomodulatory drugs (IMiDs) used in the treatment of multiple myeloma, a type of blood cancer. They have similar biological activities, but there are some differences between them:

  1. Potency: Lenalidomide is more potent than thalidomide, meaning it achieves responses at lower doses.
  2. Toxicity: Lenalidomide has a different toxicity profile compared to thalidomide, with a reduced risk of peripheral neuropathy.

An indirect comparison of lenalidomide and thalidomide-based regimens as first-line therapy for multiple myeloma patients concluded that lenalidomide seems to be more potent and less toxic than thalidomide. However, there is a lack of direct head-to-head comparisons between the two drugs, which would provide more definitive evidence of their differences in effectiveness and safety.

On this page
  • What is the Difference Between Lenalidomide and Thalidomide?
  • Comparative Table: Lenalidomide vs Thalidomide

    • Comparative Table: Lenalidomide vs Thalidomide

    Here is a table comparing the differences between lenalidomide and thalidomide:

    Property Lenalidomide Thalidomide
    Efficacy Lenalidomide-based therapy produces higher efficacy (34%-38%) than thalidomide (16%). Responses to thalidomide are seen within 3-15 weeks.
    Potency Lenalidomide is more potent than thalidomide, achieving responses at lower doses.
    Side Effects Lenalidomide is associated with a reduced risk of peripheral neuropathy compared to thalidomide. Thalidomide has a high risk of peripheral neuropathy and thromboembolism.
    Hematologic Toxicity Lenalidomide is associated with neutropenia. Thalidomide is associated with hematologic toxicity, including neutropenia and thrombocytopenia.

    In summary, lenalidomide is more potent and has a lower risk of peripheral neuropathy and thromboembolism compared to thalidomide. However, it is still associated with neutropenia.

    Read more:

    Guilherme Mazui

    Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of São Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.